A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics

Abstract

Summary Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of the coronavirus disease 2019 (COVID-19), has caused more than 179 million infections and 3.8 million deaths worldwide. Throughout the past year, multiple vaccines have already been developed and used, while some others are in the process of being developed. However, the emergence of new mutant strains of SARS-CoV-2 that have demonstrated immune-evading characteristics and an increase in infective capabilities leads to potential ineffectiveness of the vaccines against these variants. The purpose of this review article is to highlight the current understanding of the immunological mechanisms of the virus and vaccines, as well as to investigate some key variants and mutations of the virus driving the current pandemic and their impacts on current management guidelines. We also discussed new technologies being developed for the prevention, treatment, and detection of SARS-CoV-2. In this paper, we thoroughly reviewed and provided crucial information on SARS-CoV-2 virology, vaccines and drugs being used and developed for its prevention and treatment, as well as important variant strains. Our review paper will be beneficial to health care professionals and researchers so they can have a better understanding of the basic sciences, prevention, and clinical treatment of COVID-19 during the pandemic. This paper consists of the most updated information that has been available as of June 21, 2021.

References 88

1. 1.

   Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.

   Not in our library10.1016/j.jaut.2020.102433

2. 2.
   Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2 · 2020

   No notice
3. 3.

   Masters PS. Coronavirus genomic RNA packaging. Virology. 2019;537:198-207.

   Not in our library10.1016/j.virol.2019.08.031

4. 4.

   Kaur N, Singh R, Dar Z, et al. Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2. Infect Genet Evol. 2021;89:104490.

   Not in our library10.1016/j.meegid.2020.104490

5. 5.
   A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020

   No notice
6. 6.

   Bai C, Warshel A. Critical Differences between the Binding Features of the Spike Proteins of SARS-CoV-2 and SARS-CoV. J Phys Chem B. 2020;124(28):5907-5912.

   Not in our library10.1021/acs.jpcb.0c04317

7. 7.

   Huang Y, Yang C, Xu XF, et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141-1149.

   Not in our library10.1038/s41401-020-0485-4

8. 8.
   SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity · 2021

   No notice
9. 9.
   Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2) · 2020

   No notice
10. 10.

    Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80.

    Not in our library10.1016/j.cell.2020.02.052

11. 11.

    Zhou Z, Zhao N, Shu Y, et al. Effect of Gastrointestinal Symptoms in Patients With COVID-19. Gastroenterology. 2020;158(8):2294-2297.

    Not in our library10.1053/j.gastro.2020.03.020

12. 12.
    Prevalence, Mechanisms, and Implications of Gastrointestinal Symptoms in COVID-19 · 2020

    Not checked
13. 13.
    Coronavirus Disease 2019 Hospitalizations Attributable to Cardiometabolic Conditions in the United States: A Comparative Risk Assessment Analysis · 2021

    Not checked
14. 14.

    Caramelo F, Ferreira N, Oliveiros B. Estimation of risk factors for COVID-19 mortality— preliminary results. medRxiv, 2020,02.24.20027268

    Not in our library

15. 15.

    Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020;126(10):1456-1474.

    Not in our library10.1161/circresaha.120.317015

16. 16.

    Coperchini F, Chiovato L, Croce L, et al. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25.

    Not in our library10.1016/j.cytogfr.2020.05.003

17. 17.

    Faqihi F, Alharthy A, Memish ZA, et al. Comment on Hu et al: The cytokine storm and COVID-19. J Med Virol. 2021;93(2):631-633.

    Not in our library10.1002/jmv.26396

18. 18.

    Biswas S, Thakur V, Kaur P, et al. Blood clots in COVID-19 patients: Simplifying the curious mystery. Med Hypotheses. 2021;146:110371.

    Not in our library10.1016/j.mehy.2020.110371

19. 19.

    Huang Q, Wu X, Zheng X, et al. Targeting inflammation and cytokine storm in COVID-19. Pharmacol Res. 2020;159:105051.

    Not in our library10.1016/j.phrs.2020.105051

20. 20.

    Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-374.

    Not in our library10.1038/s41577-020-0311-8

21. 21.

    Zheng HY, Zhang M, Yang CX, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17(5):541-543.

    Not in our library10.1038/s41423-020-0401-3

22. 22.

    Chowdhury MA, Hossain N, Kashem MA, et al. Immune response in COVID-19: A review. J Infect Public Health. 2020;13(11):1619-1629.

    Not in our library10.1016/j.jiph.2020.07.001

23. 23.

    Lee WS, Wheatley AK, Kent SJ, et al. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5(10):1185-1191.

    Not in our library10.1038/s41564-020-00789-5

24. 24.

    Tirado SM, Yoon KJ. Antibody-dependent enhancement of virus infection and disease. Viral Immunol. 2003;16(1):69-86.

    Not in our library10.1089/088282403763635465

25. 25.
    Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies · 2021

    Not checked
26. 26.

    Huang Q, Zeng J, Yan J. COVID-19 mRNA vaccines. J Genet Genomics. 2021;48(2):107-114.

    Not in our library10.1016/j.jgg.2021.02.006

27. 27.

    Livingston EH, Malani PN, Creech CB. The Johnson & Johnson Vaccine for COVID-19. JAMA. 2021;325(15):1575.

    Not in our library10.1001/jama.2021.2927

28. 28.

    Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA, 2021, e218565. doi: 10.1001/jama.2021.8565. Epub ahead of prrnt. PMID: 34037666; PMCID: PMC8156175.

    Not in our library10.1001/jama.2021.8565

29. 29.

    Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39-51.

    Not in our library10.1016/s1473-3099(20)30831-8

30. 30.

    Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803-812.

    Not in our library10.1016/s1473-3099(20)30987-7

31. 31.
    mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection · 2020

    No notice
32. 32.
    Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans · 2021

    No notice
33. 33.

    Linares-Fernández S, Lacroix C, Exposito JY, et al. Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response. Trends Mol Med. 2020;26(3):311-323.

    Not in our library10.1016/j.molmed.2019.10.002

34. 34.
    mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability · 2021

    No notice
35. 35.

    Dyer O. Covid-19: EMA defends AstraZeneca vaccine as Germany and Canada halt rollouts. BMJ. 2021;373:n883.

    Not in our library10.1136/bmj.n883

36. 36.

    Xia S, Duan K, Zhang Y, et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020;324(10):951-960.

    Not in our library10.1001/jama.2020.15543

37. 37.

    Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-192.

    Not in our library10.1016/s1473-3099(20)30843-4

38. 38.

    Golob JL, Lugogo N, Lauring AS, et al. SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight. 2021;6(9):149187.

    Not in our library10.1172/jci.insight.149187

39. 39.

    Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845-1854.

    Not in our library10.1016/s0140-6736(20)31208-3

40. 40.

    Mallapaty S. China’s COVID vaccines are going globalbut questions remain. Nature. 2021;593(7858):178-179.

    Not in our library10.1038/d41586-021-01146-0

Cited by papers we hold 2

• РАЗРАБОТКА ВАКЦИН ОТ SARS-COV-2 · 2022
  Not checked
• The second year of pandemic in the Arctic: examining spatiotemporal dynamics of the COVID-19 “Delta wave” in Arctic regions in 2021 · 2022
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.